Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Drug

Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors

Fineline Cube Mar 21, 2024

Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors

Fineline Cube Mar 21, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from...

Company

3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics

Fineline Cube Mar 21, 2024

3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...

Company

Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales

Fineline Cube Mar 21, 2024

Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors

Fineline Cube Mar 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets

Fineline Cube Mar 20, 2024

Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement...

Company Drug

CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors

Fineline Cube Mar 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received...

Company

Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin

Fineline Cube Mar 20, 2024

Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment...

Company Deals

Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy

Fineline Cube Mar 20, 2024

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Policy / Regulatory

China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces

Fineline Cube Mar 20, 2024

The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing...

Company

Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site

Fineline Cube Mar 20, 2024

Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...

Company

Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to...

Company

WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production

Fineline Cube Mar 20, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation

Fineline Cube Mar 20, 2024

Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has...

Company Drug

Everest Medicines’ Nefegan Approved by Singapore HSA for Primary IgAN Treatment

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a China-based biotechnology company, has received marketing approval from the Singapore...

Company

Shanghai Pharmaceuticals Appoints New Chairman Amid Leadership Shake-up

Fineline Cube Mar 20, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), one of the leading pharmaceutical giants in China,...

Company Deals

AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion

Fineline Cube Mar 20, 2024

AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...

Company

China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements

Fineline Cube Mar 20, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...

Company Drug

Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin

Fineline Cube Mar 20, 2024

Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...

Company Drug

Bayer’s Elinzanetant Achieves Primary Endpoint in Late-Stage Menopause Symptom Trial

Fineline Cube Mar 20, 2024

Bayer (ETR: BAYN), a leading German pharmaceutical company, has announced positive results from a placebo-controlled...

Posts pagination

1 … 411 412 413 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.